Product Reports Resources Pricing Login Book a demo

Editas Medicine

Biotech & Life Sciences · Cambridge, United States · Founded 2013 · IPO 2016

Unlocking the promise of genome editing to deliver life-changing medicines

Valuation $288M
Revenue $41M

Investors

17 investors on Editas Medicine's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 5 investors entered at this stage
Series B+ 12 investors entered at this stage
EcoR1 Capital
Casdin Capital
Viking Global Investors
Omega Funds
T. Rowe Price
Harvard University
Alexandria Venture Investments
Khosla Ventures
Jennison Associates
Fidelity Investments
Deerfield
Boris Nikolic

Global footprint

Where Editas Medicine has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States99.4%
🇮🇳 India0.6%
2 countries shown
Web traffic by country
18K monthly visits
across markets
🇺🇸 United States46.1%
🇰🇼 Kuwait23.3%
🇦🇺 Australia13.9%
🇮🇳 India4.4%
🇬🇧 United Kingdom3.9%
Top 5 markets shown

Talent graph

The shape of Editas Medicine's talent

Dealroom maps Editas Medicine's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

5 standout operatorsDealroom-flagged across the org
2 AI specialistsincl. 1 core researchers
181 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Editas Medicine's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$69M patent portfolio · 71 active families

Estimated portfolio value
$69M
24.1% of market cap · 4.8× smaller than top peer Translate Bio ($336M)
71 active patent families
Where Editas Medicine innovates BiochemistryBioinformaticsCRISPRCas9Cell

Where Editas Medicine concentrates vs peers

Each axis is a top-10 topic across Editas Medicine and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Editas Medicine

An AI-synthesized read of the highest-engagement posts about Editas Medicine on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Editas Medicine on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.